SuperworthCumberland Pharmaceuticals profit margin CPIX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −34.9%
- Operating margin, 12 months
- −30.8%
- Net margin on a year earlier
- −25.6 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Cumberland Pharmaceuticals kept −34.9% of its revenue as net profit, with an operating margin of −30.8%.
Five years earlier its net margin was 0.1%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −8.3% | −15.2% | n/a |
| FY2024 | −17.1% | −17.0% | 82.6% |
| FY2023 | −15.9% | −24.2% | 84.7% |
| FY2022 | −13.3% | −13.6% | 78.3% |
| FY2021 | −9.7% | −21.3% | 75.5% |
| FY2020 | −8.9% | −17.0% | 76.9% |
| FY2019 | −10.3% | −27.0% | 78.4% |
| FY2018 | −17.1% | −18.1% | 81.9% |
| FY2017 | −19.4% | −9.9% | 82.1% |
| FY2016 | −2.9% | −4.3% | 82.0% |
| FY2015 | 2.2% | 3.3% | 85.2% |
| FY2014 | 6.6% | 9.6% | 86.3% |
| FY2013 | −6.6% | −11.9% | 83.0% |
| FY2012 | 12.0% | 18.1% | 89.7% |
| FY2011 | 11.1% | 19.3% | 89.5% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −34.9% | −25.6 pts | −30.8% | |
| Q1 FY26 | −23.5% | −15.5 pts | −30.4% | |
| Q4 FY25 | −8.3% | +8.8 pts | −15.2% | |
| Q3 FY25 | −10.8% | +18.8 pts | −18.3% | |
| Q2 FY25 | −9.3% | +18.2 pts | −17.0% | |
| Q1 FY25 | −8.0% | +13.7 pts | −8.0% | |
| Q4 FY24 | −17.1% | −1.2 pts | −17.0% | |
| Q3 FY24 | −29.6% | −23.4 pts | −29.3% | |
| Q2 FY24 | −27.5% | −23.1 pts | −29.0% | |
| Q1 FY24 | −21.7% | −11.7 pts | −25.5% | |
| Q4 FY23 | −15.9% | −2.6 pts | −24.2% | |
| Q3 FY23 | −6.2% | +10.8 pts | −14.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Cumberland Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| CPIXCumberland Pharmaceuticals | −34.9% |
| NATRNatures Sunshine Products | 3.7% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 11.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cumberland Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.